Donepezil has been evaluated in numerous clinical trials spanning Early Phase 1 through Phase 4 to establish its therapeutic efficacy, safety, and pharmacokinetic profiles. Sponsored by various industry and academic organizations, including Eisai Inc., Merck, and Stanford University, these studies encompass completed, active, and terminated protocols. Research primarily focuses on neurodegenerative and cognitive disorders—including Alzheimer's disease, dementia, cognitive dysfunction, Down syndrome, and Fragile X syndrome—alongside evaluations in healthy volunteers and diabetic autonomic neuropathy.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07768592 | NOT_YET_RECRUITING | Alzheimers Disease |
Eisai Inc. |
2026-10-15 | PHASE1 |
| NCT07768592 | NOT_YET_RECRUITING | Alzheimers Disease |
Eisai Inc. |
2026-10-15 | PHASE1 |
| NCT06687993 | NOT_YET_RECRUITING | Anorexia Nervosa Restricting Type |
Centre Hospitalier St Anne |
2024-11 | PHASE2 |
| NCT06687993 | NOT_YET_RECRUITING | Anorexia Nervosa Restricting Type |
Centre Hospitalier St Anne |
2024-11 | PHASE2 |
| NCT05592678 | RECRUITING | Alzheimer's Disease (AD); Dementia; Cognitive Decline; Mild Cognitivie Impairment (MCI) |
The University of Texas Health Science Center at San Antonio |
2024-08-05 | |
| NCT05592678 | RECRUITING | Alzheimer's Disease (AD); Dementia; Cognitive Decline; Mild Cognitivie Impairment (MCI) |
The University of Texas Health Science Center at San Antonio |
2024-08-05 | |
| NCT07680660 | NOT_YET_RECRUITING | Alzheimer s Disease |
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University |
2026-07-15 | |
| NCT07680660 | NOT_YET_RECRUITING | Alzheimer s Disease |
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University |
2026-07-15 | |
| NCT07066826 | RECRUITING | Alzheimer Dementia |
Wanbangde Pharmaceutical Group Co., LTD |
2025-08-29 | PHASE2; PHASE3 |
| NCT07066826 | RECRUITING | Alzheimer Dementia |
Wanbangde Pharmaceutical Group Co., LTD |
2025-08-29 | PHASE2; PHASE3 |
| NCT06518941 | NOT_YET_RECRUITING | Anorexia Nervosa |
New York State Psychiatric Institute |
2027-01 | PHASE2 |
| NCT06518941 | NOT_YET_RECRUITING | Anorexia Nervosa |
New York State Psychiatric Institute |
2027-01 | PHASE2 |
| NCT03454646 | NOT_YET_RECRUITING | Alzheimer Disease; Cholinesterase Inhibitors |
University Hospital, Bordeaux |
2024-06-01 | PHASE4 |
| NCT03454646 | NOT_YET_RECRUITING | Alzheimer Disease; Cholinesterase Inhibitors |
University Hospital, Bordeaux |
2024-06-01 | PHASE4 |
| NCT07060391 | NOT_YET_RECRUITING | Alzheimer's Disease |
Shanghai Jiao Tong University School of Medicine |
2025-07-31 | PHASE3 |
| NCT07060391 | NOT_YET_RECRUITING | Alzheimer's Disease |
Shanghai Jiao Tong University School of Medicine |
2025-07-31 | PHASE3 |
| NCT03810794 | RECRUITING | Alzheimer Disease; Cognitive Impairment |
Jian Pei,MD |
2019-03-01 | |
| NCT03810794 | RECRUITING | Alzheimer Disease; Cognitive Impairment |
Jian Pei,MD |
2019-03-01 | |
| NCT06417086 | RECRUITING | Alzheimer Disease; Cognitive Impairment |
ZhanYJ |
2024-06-01 | |
| NCT06417086 | RECRUITING | Alzheimer Disease; Cognitive Impairment |
ZhanYJ |
2024-06-01 | |
| NCT06041789 | RECRUITING | Osteoporosis |
Duke University |
2025-02-03 | PHASE2 |
| NCT06041789 | RECRUITING | Osteoporosis |
Duke University |
2025-02-03 | PHASE2 |
| NCT05042102 | RECRUITING | Alcohol Use Disorder |
VA Connecticut Healthcare System |
2022-08-08 | PHASE2 |
| NCT05042102 | RECRUITING | Alcohol Use Disorder |
VA Connecticut Healthcare System |
2022-08-08 | PHASE2 |
| NCT05438264 | ACTIVE_NOT_RECRUITING | Bilateral Sensorineural Hearing Loss |
Vanderbilt University Medical Center |
2023-03-10 | EARLY_PHASE1 |
| NCT05438264 | ACTIVE_NOT_RECRUITING | Bilateral Sensorineural Hearing Loss |
Vanderbilt University Medical Center |
2023-03-10 | EARLY_PHASE1 |
| NCT04661280 | RECRUITING | Alzheimer Disease, Early Onset |
Assistance Publique - Hôpitaux de Paris |
2022-02-10 | PHASE3 |
| NCT04661280 | RECRUITING | Alzheimer Disease, Early Onset |
Assistance Publique - Hôpitaux de Paris |
2022-02-10 | PHASE3 |
| NCT07208344 | RECRUITING | Alzheimer Disease (AD) |
Anhui Provincial Hospital |
2025-07-31 | EARLY_PHASE1 |
| NCT07208344 | RECRUITING | Alzheimer Disease (AD) |
Anhui Provincial Hospital |
2025-07-31 | EARLY_PHASE1 |
| NCT05641480 | UNKNOWN | Alzheimer Disease; Subjective Cognitive Decline; Mild Cognitive Impairment; Mild Dementia |
Shaanxi Hospital of Traditional Chinese Medicine |
2022-06-03 | |
| NCT07153991 | ACTIVE_NOT_RECRUITING | Tinnitus |
University of Sao Paulo |
2021-11-19 | PHASE4 |
| NCT07153991 | ACTIVE_NOT_RECRUITING | Tinnitus |
University of Sao Paulo |
2021-11-19 | PHASE4 |
| NCT05641480 | UNKNOWN | Alzheimer Disease; Subjective Cognitive Decline; Mild Cognitive Impairment; Mild Dementia |
Shaanxi Hospital of Traditional Chinese Medicine |
2022-06-03 | |
| NCT06774261 | COMPLETED | Alzheimer Disease; Mild Cognitive Impairment |
Helse Stavanger HF |
2025-02-01 | PHASE1 |
| NCT06774261 | COMPLETED | Alzheimer Disease; Mild Cognitive Impairment |
Helse Stavanger HF |
2025-02-01 | PHASE1 |
| NCT05345509 | ACTIVE_NOT_RECRUITING | Alzheimer Disease |
Inventage Lab., Inc. |
2023-04-01 | PHASE1; PHASE2 |
| NCT05345509 | ACTIVE_NOT_RECRUITING | Alzheimer Disease |
Inventage Lab., Inc. |
2023-04-01 | PHASE1; PHASE2 |
| NCT05709301 | UNKNOWN | Parkinson Disease; Mild Cognitive Impairment |
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau |
2023-10-01 | PHASE2 |
| NCT05709301 | UNKNOWN | Parkinson Disease; Mild Cognitive Impairment |
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau |
2023-10-01 | PHASE2 |
| NCT05078944 | COMPLETED | Alzheimer Disease 1 |
Shanghai Institute of Acupuncture, Moxibustion and Meridian |
2022-06-30 | |
| NCT05078944 | COMPLETED | Alzheimer Disease 1 |
Shanghai Institute of Acupuncture, Moxibustion and Meridian |
2022-06-30 | |
| NCT06903910 | COMPLETED | Parkinson Disease |
University of Virginia |
2024-11-01 | PHASE2 |
| NCT06903910 | COMPLETED | Parkinson Disease |
University of Virginia |
2024-11-01 | PHASE2 |
| NCT07351773 | COMPLETED | Alzheimer's Disease(AD); Cognitive Dysfunction |
Taizhou Second People's Hospital |
2025-01-26 | |
| NCT07351773 | COMPLETED | Alzheimer's Disease(AD); Cognitive Dysfunction |
Taizhou Second People's Hospital |
2025-01-26 | |
| NCT06373094 | UNKNOWN | Alzheimer Disease |
Shanghai Synergy Pharmaceutical Sciences Co., Ltd. |
2024-06-01 | PHASE1 |
| NCT06373094 | UNKNOWN | Alzheimer Disease |
Shanghai Synergy Pharmaceutical Sciences Co., Ltd. |
2024-06-01 | PHASE1 |
| NCT02255799 | COMPLETED | Traumatic Brain Injury; Memory Deficits |
Baylor College of Medicine |
2013-09-01 | PHASE3 |
| NCT02255799 | COMPLETED | Traumatic Brain Injury; Memory Deficits |
Baylor College of Medicine |
2013-09-01 | PHASE3 |
| NCT06285240 | COMPLETED | Alzheimer's Disease |
Merck Sharp & Dohme LLC |
2024-03-28 | PHASE1 |
| NCT06285240 | COMPLETED | Alzheimer's Disease |
Merck Sharp & Dohme LLC |
2024-03-28 | PHASE1 |
| NCT06127368 | UNKNOWN | Alzheimer Disease |
G2GBio, Inc. |
2024-01-03 | PHASE1 |
| NCT06127368 | UNKNOWN | Alzheimer Disease |
G2GBio, Inc. |
2024-01-03 | PHASE1 |
| NCT05538507 | UNKNOWN | Alzheimer Disease; Mild Cognitive Impairment |
Peking Union Medical College Hospital |
2022-06-01 | PHASE2 |
| NCT05538507 | UNKNOWN | Alzheimer Disease; Mild Cognitive Impairment |
Peking Union Medical College Hospital |
2022-06-01 | PHASE2 |
| NCT06373094 | Not yet recruiting | Alzheimer Disease |
Shanghai Synergy Pharmaceutical Sciences Co. Ltd.|Zhejiang Huahai Pharmaceutical Co. Ltd. |
2024-06-01 | Phase 1 |
| NCT05254639 | COMPLETED | Digestive Oncology; Supportive Care |
University Hospital, Clermont-Ferrand |
2022-06-02 | PHASE2 |
| NCT05254639 | COMPLETED | Digestive Oncology; Supportive Care |
University Hospital, Clermont-Ferrand |
2022-06-02 | PHASE2 |
| NCT06393413 | COMPLETED | Ensure the Legality and Compliance of the Testing Process |
Changchun University of Chinese Medicine |
2022-12-01 | EARLY_PHASE1 |
| NCT05518409 | UNKNOWN | Alzheimer Disease; Lewy Body Disease; Neurodegenerative Diseases |
First Affiliated Hospital of Zhejiang University |
2022-04-01 | |
| NCT06393413 | COMPLETED | Ensure the Legality and Compliance of the Testing Process |
Changchun University of Chinese Medicine |
2022-12-01 | EARLY_PHASE1 |
| NCT05518409 | UNKNOWN | Alzheimer Disease; Lewy Body Disease; Neurodegenerative Diseases |
First Affiliated Hospital of Zhejiang University |
2022-04-01 | |
| NCT04507438 | TERMINATED | Diabetes Mellitus, Type 2 |
University of Maryland, Baltimore |
2019-07-12 | PHASE2 |
| NCT04507438 | TERMINATED | Diabetes Mellitus, Type 2 |
University of Maryland, Baltimore |
2019-07-12 | PHASE2 |
| NCT04505670 | UNKNOWN | Wound Heal |
University of Maryland, Baltimore |
2020-08-30 | PHASE2 |
| NCT04505670 | UNKNOWN | Wound Heal |
University of Maryland, Baltimore |
2020-08-30 | PHASE2 |
| NCT05525780 | COMPLETED | Alzheimer Disease |
G2GBio, Inc. |
2022-08-26 | PHASE1 |
| NCT05525780 | COMPLETED | Alzheimer Disease |
G2GBio, Inc. |
2022-08-26 | PHASE1 |
| NCT05540977 | UNKNOWN | Urinary Retention After Procedure |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2022-08-01 | EARLY_PHASE1 |
| NCT05540977 | UNKNOWN | Urinary Retention After Procedure |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2022-08-01 | EARLY_PHASE1 |
| NCT05345509 | Recruiting | Alzheimer Disease |
Inventage Lab. Inc. |
2023-04-01 | Phase 1|Phase 2 |
| NCT03954613 | UNKNOWN | Alzheimer Disease; Cognitive Change |
Neutec Ar-Ge San ve Tic A.Ş |
2020-10-15 | PHASE4 |
| NCT03954613 | UNKNOWN | Alzheimer Disease; Cognitive Change |
Neutec Ar-Ge San ve Tic A.Ş |
2020-10-15 | PHASE4 |
| NCT04117178 | COMPLETED | Dementia; Dementia With Lewy Bodies; Dementia in Parkinsons Disease; Dementia Alzheimers; Alzheimer Disease |
Zealand University Hospital |
2020-02-04 | PHASE4 |
| NCT04117178 | COMPLETED | Dementia; Dementia With Lewy Bodies; Dementia in Parkinsons Disease; Dementia Alzheimers; Alzheimer Disease |
Zealand University Hospital |
2020-02-04 | PHASE4 |
| NCT04730635 | COMPLETED | Alzheimer's Disease; Mild Cognitive Impairment |
Merck Sharp & Dohme LLC |
2021-03-23 | PHASE1 |
| NCT04730635 | COMPLETED | Alzheimer's Disease; Mild Cognitive Impairment |
Merck Sharp & Dohme LLC |
2021-03-23 | PHASE1 |
| NCT03907371 | UNKNOWN | Radiation Injuries; Cognitive Impairment |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2019-05-01 | PHASE2 |
| NCT03907371 | UNKNOWN | Radiation Injuries; Cognitive Impairment |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2019-05-01 | PHASE2 |
| NCT02822573 | COMPLETED | Cognitive Dysfunction; Memory Impairment |
Wake Forest University Health Sciences |
2017-05-30 | PHASE3 |
| NCT02822573 | COMPLETED | Cognitive Dysfunction; Memory Impairment |
Wake Forest University Health Sciences |
2017-05-30 | PHASE3 |
| NCT04308304 | COMPLETED | Alzheimer's Disease |
Merck Sharp & Dohme LLC |
2021-02-16 | PHASE1 |
| NCT04308304 | COMPLETED | Alzheimer's Disease |
Merck Sharp & Dohme LLC |
2021-02-16 | PHASE1 |
| NCT02087865 | COMPLETED | Genetic Risk for Alzheimer's Disease |
The Cleveland Clinic |
2014-05 | PHASE4 |
| NCT02087865 | COMPLETED | Genetic Risk for Alzheimer's Disease |
The Cleveland Clinic |
2014-05 | PHASE4 |
| NCT04423276 | UNKNOWN | Total Knee Arthroplasty; Fracture of Head of Femur Articular Displaced; Protrusion of Intervertebral Disc |
RenJi Hospital |
2020-06-14 | PHASE4 |
| NCT04423276 | UNKNOWN | Total Knee Arthroplasty; Fracture of Head of Femur Articular Displaced; Protrusion of Intervertebral Disc |
RenJi Hospital |
2020-06-14 | PHASE4 |
| NCT00457769 | UNKNOWN | Stroke; Vascular Dementia; Memory Deficits |
Kessler Foundation |
2007-05 | PHASE1 |
| NCT02927522 | UNKNOWN | Osteoarthritis; Femoral Head Necrosis; Rheumatoid Arthritis |
RenJi Hospital |
2018-09-01 | PHASE3 |
| NCT00457769 | UNKNOWN | Stroke; Vascular Dementia; Memory Deficits |
Kessler Foundation |
2007-05 | PHASE1 |
| NCT02927522 | UNKNOWN | Osteoarthritis; Femoral Head Necrosis; Rheumatoid Arthritis |
RenJi Hospital |
2018-09-01 | PHASE3 |
| NCT04617782 | COMPLETED | Healthy Subjects |
Corium, Inc. |
2020-12-08 | PHASE1 |
| NCT04617782 | COMPLETED | Healthy Subjects |
Corium, Inc. |
2020-12-08 | PHASE1 |
| NCT05811000 | UNKNOWN | Mild Alzheimer Disease |
Mediforum Ltd., Co. |
2020-11-27 | PHASE2; PHASE3 |
| NCT05811000 | UNKNOWN | Mild Alzheimer Disease |
Mediforum Ltd., Co. |
2020-11-27 | PHASE2; PHASE3 |
| NCT04308304 | Completed | Alzheimer''s Disease |
Merck Sharp & Dohme LLC |
2021-02-16 | Phase 1 |
| NCT01584076 | COMPLETED | Amblyopia |
Boston Children's Hospital |
2012-08 | PHASE1 |
| NCT01584076 | COMPLETED | Amblyopia |
Boston Children's Hospital |
2012-08 | PHASE1 |
| NCT02487082 | TERMINATED | Autism Spectrum Disorder |
Stony Brook University |
2015-06 | PHASE2 |
| NCT02487082 | TERMINATED | Autism Spectrum Disorder |
Stony Brook University |
2015-06 | PHASE2 |
| NCT04617782 | Completed | Healthy Subjects |
Corium Inc. |
2020-12-08 | Phase 1 |
| NCT04134416 | COMPLETED | Aphasia; Stroke |
University of Malaga |
2019-01-08 | PHASE3 |
| NCT04134416 | COMPLETED | Aphasia; Stroke |
University of Malaga |
2019-01-08 | PHASE3 |
| NCT03932916 | COMPLETED | AD |
Shanghai Synergy Pharmaceutical Sciences Co., Ltd. |
2019-07-02 | PHASE1 |
| NCT03932916 | COMPLETED | AD |
Shanghai Synergy Pharmaceutical Sciences Co., Ltd. |
2019-07-02 | PHASE1 |
| NCT03197740 | COMPLETED | Alzheimer Disease |
Icure Pharmaceutical Inc. |
2017-10-12 | PHASE3 |
| NCT03197740 | COMPLETED | Alzheimer Disease |
Icure Pharmaceutical Inc. |
2017-10-12 | PHASE3 |
| NCT03090516 | UNKNOWN | Alzheimer's |
The First Affiliated Hospital with Nanjing Medical University |
2016-08-10 | PHASE2; PHASE3 |
| NCT03090516 | UNKNOWN | Alzheimer's |
The First Affiliated Hospital with Nanjing Medical University |
2016-08-10 | PHASE2; PHASE3 |
| NCT03740178 | WITHDRAWN | Alzheimer's Disease; Mild Cognitive Impairment |
Merck Sharp & Dohme LLC |
2019-09-27 | PHASE1 |
| NCT03740178 | WITHDRAWN | Alzheimer's Disease; Mild Cognitive Impairment |
Merck Sharp & Dohme LLC |
2019-09-27 | PHASE1 |
| NCT04318639 | COMPLETED | Alcohol Use Disorder; Mild Cognitive Impairment |
VA Connecticut Healthcare System |
2018-08-17 | PHASE2; PHASE3 |
| NCT04318639 | COMPLETED | Alcohol Use Disorder; Mild Cognitive Impairment |
VA Connecticut Healthcare System |
2018-08-17 | PHASE2; PHASE3 |
| NCT04013477 | COMPLETED | Healthy |
Dong-A ST Co., Ltd. |
2019-06-18 | PHASE1 |
| NCT04013477 | COMPLETED | Healthy |
Dong-A ST Co., Ltd. |
2019-06-18 | PHASE1 |
| NCT02580305 | COMPLETED | Alzheimer's Disease |
Suven Life Sciences Limited |
2015-09 | PHASE2 |
| NCT02580305 | COMPLETED | Alzheimer's Disease |
Suven Life Sciences Limited |
2015-09 | PHASE2 |
| NCT03698695 | COMPLETED | Cognitive Impairment; Alzheimer Disease |
Theranexus |
2018-09-27 | PHASE1 |
| NCT03698695 | COMPLETED | Cognitive Impairment; Alzheimer Disease |
Theranexus |
2018-09-27 | PHASE1 |
| NCT03184467 | COMPLETED | Alzheimer Disease |
GemVax & Kael |
2017-09-05 | PHASE2 |
| NCT03184467 | COMPLETED | Alzheimer Disease |
GemVax & Kael |
2017-09-05 | PHASE2 |
| NCT03905096 | COMPLETED | Healthy |
Boehringer Ingelheim |
2019-04-12 | PHASE1 |
| NCT03905096 | COMPLETED | Healthy |
Boehringer Ingelheim |
2019-04-12 | PHASE1 |
| NCT02450786 | UNKNOWN | Parkinson's Disease |
Yonsei University |
2015-06 | PHASE2 |
| NCT02450786 | UNKNOWN | Parkinson's Disease |
Yonsei University |
2015-06 | PHASE2 |
| NCT02305836 | UNKNOWN | Cognitive Impairment |
Guang'anmen Hospital of China Academy of Chinese Medical Sciences |
2017-06 | PHASE2 |
| NCT02305836 | UNKNOWN | Cognitive Impairment |
Guang'anmen Hospital of China Academy of Chinese Medical Sciences |
2017-06 | PHASE2 |
| NCT03599726 | COMPLETED | Parkinson Disease |
Oregon Health and Science University |
2018-07-30 | EARLY_PHASE1 |
| NCT03599726 | COMPLETED | Parkinson Disease |
Oregon Health and Science University |
2018-07-30 | EARLY_PHASE1 |
| NCT01951118 | COMPLETED | Alzheimer Disease; Mild Cognitive Impairment; Delirium, Dementia, Amnestic, Cognitive Disorders |
New York State Psychiatric Institute |
2013-10 | PHASE4 |
| NCT01951118 | COMPLETED | Alzheimer Disease; Mild Cognitive Impairment; Delirium, Dementia, Amnestic, Cognitive Disorders |
New York State Psychiatric Institute |
2013-10 | PHASE4 |
| NCT02573519 | TERMINATED | Diabetic Autonomic Neuropathy; Gastrointestinal Motility Disorder; Diabetes Mellitus; Change of Transit or Circulation |
University of Aarhus |
2015-10 | |
| NCT02573519 | TERMINATED | Diabetic Autonomic Neuropathy; Gastrointestinal Motility Disorder; Diabetes Mellitus; Change of Transit or Circulation |
University of Aarhus |
2015-10 | |
| NCT03055741 | COMPLETED | Mild-moderate Alzheimer's Disease |
Daehwa Pharmaceutical Co., Ltd. |
2016-12-28 | PHASE2 |
| NCT03055741 | COMPLETED | Mild-moderate Alzheimer's Disease |
Daehwa Pharmaceutical Co., Ltd. |
2016-12-28 | PHASE2 |
| NCT00934531 | COMPLETED | Falls; Gait; Balance; Mild Cognitive Impairment (MCI) |
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's |
2009-09 | |
| NCT02787746 | COMPLETED | Alzheimer's Disease |
Beijing Friendship Hospital |
2016-04 | PHASE4 |
| NCT00934531 | COMPLETED | Falls; Gait; Balance; Mild Cognitive Impairment (MCI) |
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's |
2009-09 | |
| NCT02787746 | COMPLETED | Alzheimer's Disease |
Beijing Friendship Hospital |
2016-04 | PHASE4 |
| NCT03109314 | COMPLETED | Amblyopia |
Dennis Levi |
2012-05-01 | PHASE4 |
| NCT03109314 | COMPLETED | Amblyopia |
Dennis Levi |
2012-05-01 | PHASE4 |
| NCT01255046 | UNKNOWN | Alzheimer Disease |
Sinphar Pharmaceutical Co., Ltd |
2015-12 | PHASE2 |
| NCT01255046 | UNKNOWN | Alzheimer Disease |
Sinphar Pharmaceutical Co., Ltd |
2015-12 | PHASE2 |
| NCT03299257 | UNKNOWN | OSA; Sleepiness |
Associação Fundo de Incentivo à Pesquisa |
2018-07-06 | PHASE4 |
| NCT03316898 | WITHDRAWN | Alzheimer's Disease |
Allergan |
2018-09-30 | PHASE1 |
| NCT03316898 | WITHDRAWN | Alzheimer's Disease |
Allergan |
2018-09-30 | PHASE1 |
| NCT03299257 | UNKNOWN | OSA; Sleepiness |
Associação Fundo de Incentivo à Pesquisa |
2018-07-06 | PHASE4 |
| NCT02648906 | UNKNOWN | Alzheimer Disease |
Daewoong Pharmaceutical Co. LTD. |
2015-07 | PHASE4 |
| NCT02648906 | UNKNOWN | Alzheimer Disease |
Daewoong Pharmaceutical Co. LTD. |
2015-07 | PHASE4 |
| NCT03011476 | UNKNOWN | Parkinson Disease |
Kyung Hee University Hospital |
2017-04-11 | PHASE4 |
| NCT03011476 | UNKNOWN | Parkinson Disease |
Kyung Hee University Hospital |
2017-04-11 | PHASE4 |
| NCT02660983 | COMPLETED | Dementia Associated With Cerebrovascular Disease |
Eisai Co., Ltd. |
2013-08-05 | PHASE4 |
| NCT02660983 | COMPLETED | Dementia Associated With Cerebrovascular Disease |
Eisai Co., Ltd. |
2013-08-05 | PHASE4 |
| NCT03432195 | COMPLETED | Alzheimer's Disease |
Corium, Inc. |
2018-01-31 | PHASE1 |
| NCT03432195 | COMPLETED | Alzheimer's Disease |
Corium, Inc. |
2018-01-31 | PHASE1 |
| NCT03438604 | COMPLETED | Alzheimer's Disease |
Corium, Inc. |
2018-02-13 | PHASE1 |
| NCT03438604 | COMPLETED | Alzheimer's Disease |
Corium, Inc. |
2018-02-13 | PHASE1 |
| NCT03569579 | COMPLETED | Central Nervous System Diseases |
Chong Kun Dang Pharmaceutical |
2018-04-16 | PHASE1 |
| NCT03569579 | COMPLETED | Central Nervous System Diseases |
Chong Kun Dang Pharmaceutical |
2018-04-16 | PHASE1 |
| NCT02703636 | COMPLETED | Mild to Moderate Alzheimer's Disease |
Novartis Pharmaceuticals |
2016-05-09 | PHASE4 |
| NCT02703636 | COMPLETED | Mild to Moderate Alzheimer's Disease |
Novartis Pharmaceuticals |
2016-05-09 | PHASE4 |
| NCT03259958 | COMPLETED | Alzheimer's Disease |
Corium, Inc. |
2017-10-30 | PHASE1 |
| NCT03259958 | COMPLETED | Alzheimer's Disease |
Corium, Inc. |
2017-10-30 | PHASE1 |
| NCT03397862 | COMPLETED | Skin Irritation; Sensitization |
Corium, Inc. |
2017-11-14 | PHASE1 |
| NCT03397862 | COMPLETED | Skin Irritation; Sensitization |
Corium, Inc. |
2017-11-14 | PHASE1 |
| NCT03151382 | UNKNOWN | Alzheimer Disease; Cognitive Function |
Zhejiang Provincial People's Hospital |
2017-05-20 | PHASE4 |
| NCT03151382 | UNKNOWN | Alzheimer Disease; Cognitive Function |
Zhejiang Provincial People's Hospital |
2017-05-20 | PHASE4 |
| NCT01098383 | UNKNOWN | Autism |
Sheba Medical Center |
2010-03 | PHASE4 |
| NCT01098383 | UNKNOWN | Autism |
Sheba Medical Center |
2010-03 | PHASE4 |
| NCT02857244 | WITHDRAWN | Parkinson's Disease |
University of Chicago |
2016-11 | PHASE2 |
| NCT02857244 | WITHDRAWN | Parkinson's Disease |
University of Chicago |
2016-11 | PHASE2 |
| NCT02549196 | COMPLETED | Dementia of Alzheimer's Type |
Chase Pharmaceuticals Corporation, an affiliate of Allergan plc |
2015-10-07 | PHASE2 |
| NCT02549196 | COMPLETED | Dementia of Alzheimer's Type |
Chase Pharmaceuticals Corporation, an affiliate of Allergan plc |
2015-10-07 | PHASE2 |
| NCT02337907 | COMPLETED | Alzheimer Disease |
Boehringer Ingelheim |
2015-01-21 | PHASE2 |
| NCT02337907 | COMPLETED | Alzheimer Disease |
Boehringer Ingelheim |
2015-01-21 | PHASE2 |
| NCT02626572 | COMPLETED | Alzheimer's Disease |
Institut de Recherches Internationales Servier |
2015-02 | PHASE2 |
| NCT02585934 | COMPLETED | Alzheimer's Disease |
Axovant Sciences Ltd. |
2015-10 | PHASE3 |
| NCT02626572 | COMPLETED | Alzheimer's Disease |
Institut de Recherches Internationales Servier |
2015-02 | PHASE2 |
| NCT02585934 | COMPLETED | Alzheimer's Disease |
Axovant Sciences Ltd. |
2015-10 | PHASE3 |
| NCT02918266 | TERMINATED | Healthy Volunteers |
Takeda |
2016-11-21 | PHASE1 |
| NCT02918266 | TERMINATED | Healthy Volunteers |
Takeda |
2016-11-21 | PHASE1 |
| NCT02968719 | COMPLETED | Alzheimer Disease |
Corium, Inc. |
2016-11 | PHASE1 |
| NCT02968719 | COMPLETED | Alzheimer Disease |
Corium, Inc. |
2016-11 | PHASE1 |
| NCT02079246 | COMPLETED | Alzheimer's Disease |
H. Lundbeck A/S |
2014-04-07 | PHASE3 |
| NCT02079246 | COMPLETED | Alzheimer's Disease |
H. Lundbeck A/S |
2014-04-07 | PHASE3 |
| NCT02206620 | COMPLETED | Parkinson's Disease |
Oregon Health and Science University |
2014-07 | PHASE2 |
| NCT02206620 | COMPLETED | Parkinson's Disease |
Oregon Health and Science University |
2014-07 | PHASE2 |
| NCT02374567 | TERMINATED | Dementia; Depression; Schizophrenia; Psychosomatic Disorders; Anxiety Disorders |
Hannover Medical School |
2015-01 | PHASE3 |
| NCT02374567 | TERMINATED | Dementia; Depression; Schizophrenia; Psychosomatic Disorders; Anxiety Disorders |
Hannover Medical School |
2015-01 | PHASE3 |
| NCT02769065 | TERMINATED | Alzheimer Disease; Healthy Volunteers |
Takeda |
2016-05-05 | PHASE1 |
| NCT02769065 | TERMINATED | Alzheimer Disease; Healthy Volunteers |
Takeda |
2016-05-05 | PHASE1 |
| NCT03030105 | COMPLETED | Alzheimer Disease |
Tetra Discovery Partners |
2017-01 | PHASE1 |
| NCT02453932 | COMPLETED | Vascular Dementia |
Dongzhimen Hospital, Beijing |
2013-10 | PHASE3 |
| NCT03030105 | COMPLETED | Alzheimer Disease |
Tetra Discovery Partners |
2017-01 | PHASE1 |
| NCT02453932 | COMPLETED | Vascular Dementia |
Dongzhimen Hospital, Beijing |
2013-10 | PHASE3 |
| NCT02331771 | TERMINATED | Memory Impairment |
Porter Adventist Hospital |
2015-09-24 | |
| NCT02331771 | TERMINATED | Memory Impairment |
Porter Adventist Hospital |
2015-09-24 | |
| NCT02006641 | COMPLETED | Alzheimer's Disease |
H. Lundbeck A/S |
2014-02 | PHASE3 |
| NCT02006641 | COMPLETED | Alzheimer's Disease |
H. Lundbeck A/S |
2014-02 | PHASE3 |
| NCT02222727 | TERMINATED | Aneurysmal Subarachnoid Hemorrhage; Delayed Neurological Deficit; Delayed Cerebral Ischemia; Vasospasm |
St George's, University of London |
2014-01 | PHASE2 |
| NCT02222727 | TERMINATED | Aneurysmal Subarachnoid Hemorrhage; Delayed Neurological Deficit; Delayed Cerebral Ischemia; Vasospasm |
St George's, University of London |
2014-01 | PHASE2 |
| NCT02415062 | UNKNOWN | Parkinson's Disease |
Inje University |
2015-07 | PHASE2 |
| NCT02415062 | UNKNOWN | Parkinson's Disease |
Inje University |
2015-07 | PHASE2 |
| NCT02094053 | COMPLETED | Down Syndrome |
Eisai Co., Ltd. |
2013-09-12 | PHASE2 |
| NCT02094053 | COMPLETED | Down Syndrome |
Eisai Co., Ltd. |
2013-09-12 | PHASE2 |
| NCT01822951 | WITHDRAWN | Alzheimer Disease |
Ever Neuro Pharma GmbH |
PHASE4 | |
| NCT01822951 | WITHDRAWN | Alzheimer Disease |
Ever Neuro Pharma GmbH |
PHASE4 | |
| NCT02550665 | COMPLETED | Alzheimer's Disease |
Asan Medical Center |
2014-12 | PHASE3 |
| NCT02550665 | COMPLETED | Alzheimer's Disease |
Asan Medical Center |
2014-12 | PHASE3 |
| NCT02064920 | COMPLETED | Alzheimer's Disease |
Merck Sharp & Dohme LLC |
2014-04-22 | PHASE2 |
| NCT02064920 | COMPLETED | Alzheimer's Disease |
Merck Sharp & Dohme LLC |
2014-04-22 | PHASE2 |
| NCT01955161 | COMPLETED | Alzheimer's Disease |
H. Lundbeck A/S |
2013-10 | PHASE3 |
| NCT01955161 | COMPLETED | Alzheimer's Disease |
H. Lundbeck A/S |
2013-10 | PHASE3 |
| NCT02635750 | COMPLETED | Healthy |
Boehringer Ingelheim |
2016-01-15 | PHASE1 |
| NCT02635750 | COMPLETED | Healthy |
Boehringer Ingelheim |
2016-01-15 | PHASE1 |
| NCT01845636 | COMPLETED | Mild Cognitive Impairment |
New York State Psychiatric Institute |
2012-08 | PHASE4 |
| NCT01845636 | COMPLETED | Mild Cognitive Impairment |
New York State Psychiatric Institute |
2012-08 | PHASE4 |
| NCT00594633 | COMPLETED | Brain Tumor; Brain Cancer; Cns Cancer; Cognitive Dysfunction |
Memorial Sloan Kettering Cancer Center |
2004-10 | PHASE1 |
| NCT01658228 | COMPLETED | Depression; Mild Cognitive Impairment |
New York State Psychiatric Institute |
2011-09 | PHASE4 |
| NCT00594633 | COMPLETED | Brain Tumor; Brain Cancer; Cns Cancer; Cognitive Dysfunction |
Memorial Sloan Kettering Cancer Center |
2004-10 | PHASE1 |
| NCT01658228 | COMPLETED | Depression; Mild Cognitive Impairment |
New York State Psychiatric Institute |
2011-09 | PHASE4 |
| NCT01633593 | TERMINATED | Elderly; Delirium of Unknown (Axis III) Etiology; Intensive Care (ICU) Myopathy |
University of Sao Paulo |
2012-08 | PHASE4 |
| NCT01887132 | TERMINATED | Autism Spectrum Disorders |
National Institute of Mental Health (NIMH) |
2013-06 | PHASE2 |
| NCT01887132 | TERMINATED | Autism Spectrum Disorders |
National Institute of Mental Health (NIMH) |
2013-06 | PHASE2 |
| NCT01633593 | TERMINATED | Elderly; Delirium of Unknown (Axis III) Etiology; Intensive Care (ICU) Myopathy |
University of Sao Paulo |
2012-08 | PHASE4 |
| NCT01362686 | TERMINATED | Dementia; Alzheimer's Disease |
Indiana University |
2011-04 | |
| NCT01362686 | TERMINATED | Dementia; Alzheimer's Disease |
Indiana University |
2011-04 | |
| NCT01712074 | TERMINATED | Alzheimer's Disease |
Pfizer |
2012-11 | PHASE2 |
| NCT01712074 | TERMINATED | Alzheimer's Disease |
Pfizer |
2012-11 | PHASE2 |
| NCT02406261 | COMPLETED | Healthy |
AstraZeneca |
2015-04-30 | PHASE1 |
| NCT02406261 | COMPLETED | Healthy |
AstraZeneca |
2015-04-30 | PHASE1 |
| NCT01940952 | UNKNOWN | Alzheimer's Disease |
Samsung Medical Center |
2013-09 | PHASE3 |
| NCT01940952 | UNKNOWN | Alzheimer's Disease |
Samsung Medical Center |
2013-09 | PHASE3 |
| NCT01677754 | COMPLETED | Alzheimer's Disease |
Hoffmann-La Roche |
2012-10-24 | PHASE2 |
| NCT01677754 | COMPLETED | Alzheimer's Disease |
Hoffmann-La Roche |
2012-10-24 | PHASE2 |
| NCT02097056 | COMPLETED | Alzheimer's Disease |
Eisai Korea Inc. |
2014-02 | PHASE4 |
| NCT02264353 | COMPLETED | Obstructive Sleep Apnea |
University of California, San Diego |
2014-09 | PHASE4 |
| NCT02097056 | COMPLETED | Alzheimer's Disease |
Eisai Korea Inc. |
2014-02 | PHASE4 |
| NCT02264353 | COMPLETED | Obstructive Sleep Apnea |
University of California, San Diego |
2014-09 | PHASE4 |
| NCT00776347 | COMPLETED | Dementia With Lewy Bodies (DLB) |
Osaka University |
2008-10 | |
| NCT00776347 | COMPLETED | Dementia With Lewy Bodies (DLB) |
Osaka University |
2008-10 | |
| NCT01539031 | COMPLETED | Alzheimer's Type Dementia |
Eisai Co., Ltd. |
2012-03 | PHASE3 |
| NCT01539031 | COMPLETED | Alzheimer's Type Dementia |
Eisai Co., Ltd. |
2012-03 | PHASE3 |
| NCT02178124 | COMPLETED | Alzheimer Disease |
Icure Pharmaceutical Inc. |
2014-07 | PHASE1 |
| NCT02178124 | COMPLETED | Alzheimer Disease |
Icure Pharmaceutical Inc. |
2014-07 | PHASE1 |
| NCT01461174 | COMPLETED | Healthy |
Qualissima |
2011-11 | PHASE1 |
| NCT01461174 | COMPLETED | Healthy |
Qualissima |
2011-11 | PHASE1 |
| NCT01014858 | TERMINATED | Parkinson's Disease |
Newcastle-upon-Tyne Hospitals NHS Trust |
2013-01 | PHASE3 |
| NCT01014858 | TERMINATED | Parkinson's Disease |
Newcastle-upon-Tyne Hospitals NHS Trust |
2013-01 | PHASE3 |
| NCT01738295 | COMPLETED | Healthy |
Université de Montréal |
2013-01 | |
| NCT01849042 | UNKNOWN | Alzheimer's Disease; Dementia |
Konkuk University Medical Center |
2013-01 | PHASE4 |
| NCT01738295 | COMPLETED | Healthy |
Université de Montréal |
2013-01 | |
| NCT01849042 | UNKNOWN | Alzheimer's Disease; Dementia |
Konkuk University Medical Center |
2013-01 | PHASE4 |
| NCT02570581 | COMPLETED | Healthy |
Centre Hospitalier Universitaire de Nice |
2014-06 | PHASE1 |
| NCT02570581 | COMPLETED | Healthy |
Centre Hospitalier Universitaire de Nice |
2014-06 | PHASE1 |
| NCT01404169 | COMPLETED | Alzheimer's Type Dementia |
Eisai Limited |
2011-09 | PHASE3 |
| NCT01404169 | COMPLETED | Alzheimer's Type Dementia |
Eisai Limited |
2011-09 | PHASE3 |
| NCT01466088 | COMPLETED | Alzheimer's Disease |
Targacept Inc. |
2011-10 | PHASE2 |
| NCT01466088 | COMPLETED | Alzheimer's Disease |
Targacept Inc. |
2011-10 | PHASE2 |
| NCT02051335 | COMPLETED | Memory Impairment; Alzheimer's Disease |
AstraZeneca |
2014-01 | PHASE1 |
| NCT02051335 | COMPLETED | Memory Impairment; Alzheimer's Disease |
AstraZeneca |
2014-01 | PHASE1 |
| NCT02055703 | COMPLETED | Healthy Subjects |
Eisai Inc. |
2014-01 | PHASE1 |
| NCT02055703 | COMPLETED | Healthy Subjects |
Eisai Inc. |
2014-01 | PHASE1 |
| NCT01120626 | COMPLETED | Fragile X Syndrome |
Stanford University |
2009-09 | PHASE2 |
| NCT01529619 | COMPLETED | Alzheimer's Disease |
Novartis Pharmaceuticals |
2012-03 | PHASE4 |
| NCT01529619 | COMPLETED | Alzheimer's Disease |
Novartis Pharmaceuticals |
2012-03 | PHASE4 |
| NCT01860625 | COMPLETED | Alzheimer Disease |
Icure Pharmaceutical Inc. |
2013-04 | PHASE1 |
| NCT01120626 | COMPLETED | Fragile X Syndrome |
Stanford University |
2009-09 | PHASE2 |
| NCT01860625 | COMPLETED | Alzheimer Disease |
Icure Pharmaceutical Inc. |
2013-04 | PHASE1 |
| NCT01442766 | WITHDRAWN | Acute Stroke |
Imperial College London |
2011-11 | PHASE1; PHASE2 |
| NCT01527916 | COMPLETED | Alzheimer's Disease |
AbbVie (prior sponsor, Abbott) |
2012-02 | PHASE2 |
| NCT01442766 | WITHDRAWN | Acute Stroke |
Imperial College London |
2011-11 | PHASE1; PHASE2 |
| NCT01527916 | COMPLETED | Alzheimer's Disease |
AbbVie (prior sponsor, Abbott) |
2012-02 | PHASE2 |
| NCT01743976 | TERMINATED | Neuropathic Pain |
Wake Forest University |
2012-12 | PHASE4 |
| NCT01743976 | TERMINATED | Neuropathic Pain |
Wake Forest University |
2012-12 | PHASE4 |
| NCT01466270 | COMPLETED | Anxiety Disorder; Breast Cancer; Cognition Disorders; Depression; Fatigue; Sleep Disorders |
Wake Forest University Health Sciences |
2012-07 | PHASE2 |
| NCT01466270 | COMPLETED | Anxiety Disorder; Breast Cancer; Cognition Disorders; Depression; Fatigue; Sleep Disorders |
Wake Forest University Health Sciences |
2012-07 | PHASE2 |
| NCT01903824 | COMPLETED | Cognitive Impairment |
Teva Branded Pharmaceutical Products R&D, Inc. |
2013-08 | PHASE1 |
| NCT01903824 | COMPLETED | Cognitive Impairment |
Teva Branded Pharmaceutical Products R&D, Inc. |
2013-08 | PHASE1 |
| NCT00750529 | COMPLETED | Alzheimer's Disease |
University Hospital, Clermont-Ferrand |
2008-11 | PHASE1 |
| NCT00750529 | COMPLETED | Alzheimer's Disease |
University Hospital, Clermont-Ferrand |
2008-11 | PHASE1 |
| NCT00868010 | UNKNOWN | Ischemic Stroke |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
2009-03 | PHASE3 |
| NCT00868010 | UNKNOWN | Ischemic Stroke |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
2009-03 | PHASE3 |
| NCT01478633 | COMPLETED | Alzheimer's Disease |
Janssen Pharmaceutical K.K. |
2011-09 | PHASE4 |
| NCT01478633 | COMPLETED | Alzheimer's Disease |
Janssen Pharmaceutical K.K. |
2011-09 | PHASE4 |
| NCT00619983 | TERMINATED | Diabetic Neuropathic Pain; Chronic Low Back Pain |
Wake Forest University |
2008-02 | PHASE4 |
| NCT01495195 | COMPLETED | Cocaine Use Disorders |
Midwest Biomedical Research |
2012-02 | PHASE2 |
| NCT00619983 | TERMINATED | Diabetic Neuropathic Pain; Chronic Low Back Pain |
Wake Forest University |
2008-02 | PHASE4 |
| NCT01495195 | COMPLETED | Cocaine Use Disorders |
Midwest Biomedical Research |
2012-02 | PHASE2 |
| NCT01278407 | COMPLETED | Dementia With Lewy Bodies (DLB) |
Eisai Co., Ltd. |
2011-02 | PHASE3 |
| NCT01278407 | COMPLETED | Dementia With Lewy Bodies (DLB) |
Eisai Co., Ltd. |
2011-02 | PHASE3 |
| NCT00586196 | COMPLETED | Delirium |
Beth Israel Deaconess Medical Center |
2007-01 | PHASE2 |
| NCT00586196 | COMPLETED | Delirium |
Beth Israel Deaconess Medical Center |
2007-01 | PHASE2 |
| NCT01379001 | COMPLETED | Cholinergic Function |
Hebrew SeniorLife |
2008-07 | |
| NCT01266525 | COMPLETED | Dementia Alzheimer's Type |
Sanofi |
2011-02 | PHASE2 |
| NCT01266525 | COMPLETED | Dementia Alzheimer's Type |
Sanofi |
2011-02 | PHASE2 |
| NCT01379001 | COMPLETED | Cholinergic Function |
Hebrew SeniorLife |
2008-07 | |
| NCT01487395 | COMPLETED | Alzheimer Disease; Battery |
University Hospital, Lille |
2011-12 | PHASE1 |
| NCT01487395 | COMPLETED | Alzheimer Disease; Battery |
University Hospital, Lille |
2011-12 | PHASE1 |
| NCT00408525 | COMPLETED | Alzheimer's Disease |
Vanderbilt University |
2006-12 | PHASE1 |
| NCT00408525 | COMPLETED | Alzheimer's Disease |
Vanderbilt University |
2006-12 | PHASE1 |
| NCT01485185 | COMPLETED | Pain, Neuropathic |
GlaxoSmithKline |
2011-10-11 | PHASE1 |
| NCT01485185 | COMPLETED | Pain, Neuropathic |
GlaxoSmithKline |
2011-10-11 | PHASE1 |
| NCT00369785 | COMPLETED | Brain Tumors; Metastatic Disease |
Wake Forest University Health Sciences |
2008-02 | PHASE3 |
| NCT00369785 | COMPLETED | Brain Tumors; Metastatic Disease |
Wake Forest University Health Sciences |
2008-02 | PHASE3 |
| NCT01082965 | TERMINATED | Alzheimer's Disease |
Pfizer |
2010-07 | |
| NCT01082965 | TERMINATED | Alzheimer's Disease |
Pfizer |
2010-07 | |
| NCT01490567 | UNKNOWN | Impaired Cognition; Schizophrenia |
Central South University |
2011-06 | PHASE4 |
| NCT01409564 | COMPLETED | Alzheimer's Dementia |
Seoul National University Hospital |
2010-05 | PHASE4 |
| NCT01409564 | COMPLETED | Alzheimer's Dementia |
Seoul National University Hospital |
2010-05 | PHASE4 |
| NCT01490567 | UNKNOWN | Impaired Cognition; Schizophrenia |
Central South University |
2011-06 | PHASE4 |
| NCT01521117 | COMPLETED | Parkinson's Disease |
Oregon Health and Science University |
2011-12 | PHASE4 |
| NCT01521117 | COMPLETED | Parkinson's Disease |
Oregon Health and Science University |
2011-12 | PHASE4 |
| NCT00866060 | UNKNOWN | Moderate to Severe Alzheimer's Disease |
King's College London |
2008-02 | PHASE4 |
| NCT00866060 | UNKNOWN | Moderate to Severe Alzheimer's Disease |
King's College London |
2008-02 | PHASE4 |
| NCT01250977 | COMPLETED | Smoking |
Abramson Cancer Center at Penn Medicine |
2011-01-11 | PHASE2 |
| NCT01250977 | COMPLETED | Smoking |
Abramson Cancer Center at Penn Medicine |
2011-01-11 | PHASE2 |
| NCT00829374 | COMPLETED | Alzheimer's Disease |
Medivation, Inc. |
2009-03 | PHASE3 |
| NCT01019421 | COMPLETED | Alzheimer's Disease |
H. Lundbeck A/S |
2009-12 | PHASE2 |
| NCT00829374 | COMPLETED | Alzheimer's Disease |
Medivation, Inc. |
2009-03 | PHASE3 |
| NCT01019421 | COMPLETED | Alzheimer's Disease |
H. Lundbeck A/S |
2009-12 | PHASE2 |
| NCT01406145 | COMPLETED | Alzheimer's Disease |
Astellas Pharma Inc |
2011-06-16 | PHASE1 |
| NCT01406145 | COMPLETED | Alzheimer's Disease |
Astellas Pharma Inc |
2011-06-16 | PHASE1 |
| NCT01506752 | COMPLETED | Healthy Adult |
Eisai Co., Ltd. |
2011-07 | PHASE1 |
| NCT01506752 | COMPLETED | Healthy Adult |
Eisai Co., Ltd. |
2011-07 | PHASE1 |
| NCT01213355 | COMPLETED | Healthy |
Pfizer |
2011-04 | PHASE1 |
| NCT01213355 | COMPLETED | Healthy |
Pfizer |
2011-04 | PHASE1 |
| NCT01345864 | TERMINATED | Healthy |
Pfizer |
2011-05 | PHASE1 |
| NCT01137526 | COMPLETED | Alzheimer's Disease |
AbbVie (prior sponsor, Abbott) |
2010-05 | PHASE2 |
| NCT01345864 | TERMINATED | Healthy |
Pfizer |
2011-05 | PHASE1 |
| NCT01137526 | COMPLETED | Alzheimer's Disease |
AbbVie (prior sponsor, Abbott) |
2010-05 | PHASE2 |
| NCT00842816 | COMPLETED | Alzheimer's Disease |
Sonexa Therapeutics, Inc. |
2009-02 | PHASE2 |
| NCT00895895 | TERMINATED | Alzheimer Disease |
Pfizer |
2009-05 | PHASE2 |
| NCT00842816 | COMPLETED | Alzheimer's Disease |
Sonexa Therapeutics, Inc. |
2009-02 | PHASE2 |
| NCT00895895 | TERMINATED | Alzheimer Disease |
Pfizer |
2009-05 | PHASE2 |
| NCT01506739 | COMPLETED | Healthy Adult |
Eisai Co., Ltd. |
2011-03 | PHASE1 |
| NCT01506739 | COMPLETED | Healthy Adult |
Eisai Co., Ltd. |
2011-03 | PHASE1 |
| NCT00967707 | COMPLETED | Post-traumatic Neuropathic Pain |
Uppsala University |
2009-08 | PHASE2 |
| NCT00967707 | COMPLETED | Post-traumatic Neuropathic Pain |
Uppsala University |
2009-08 | PHASE2 |
| NCT01125683 | TERMINATED | Alzheimer´s Disease |
AstraZeneca |
2010-06 | PHASE2 |
| NCT01125683 | TERMINATED | Alzheimer´s Disease |
AstraZeneca |
2010-06 | PHASE2 |
| NCT01245530 | COMPLETED | Alzheimer Type Dementia |
Whanin Pharmaceutical Company |
2008-06 | PHASE3 |
| NCT01018875 | COMPLETED | Alzheimer's Disease |
AbbVie (prior sponsor, Abbott) |
2009-12 | PHASE2 |
| NCT01245530 | COMPLETED | Alzheimer Type Dementia |
Whanin Pharmaceutical Company |
2008-06 | PHASE3 |
| NCT01018875 | COMPLETED | Alzheimer's Disease |
AbbVie (prior sponsor, Abbott) |
2009-12 | PHASE2 |
| NCT00695136 | COMPLETED | Autism; Cognition Disorder |
National Institute of Mental Health (NIMH) |
2008-06 | PHASE1; PHASE2 |
| NCT01024660 | COMPLETED | Alzheimer's Disease |
AstraZeneca |
2009-12 | EARLY_PHASE1 |
| NCT00695136 | COMPLETED | Autism; Cognition Disorder |
National Institute of Mental Health (NIMH) |
2008-06 | PHASE1; PHASE2 |
| NCT01024660 | COMPLETED | Alzheimer's Disease |
AstraZeneca |
2009-12 | EARLY_PHASE1 |
| NCT00884507 | COMPLETED | Alzheimer's Disease |
Hoffmann-La Roche |
2009-05 | PHASE2 |
| NCT00948909 | COMPLETED | Alzheimer's Disease |
AbbVie (prior sponsor, Abbott) |
2009-10 | PHASE2 |
| NCT00884507 | COMPLETED | Alzheimer's Disease |
Hoffmann-La Roche |
2009-05 | PHASE2 |
| NCT00948909 | COMPLETED | Alzheimer's Disease |
AbbVie (prior sponsor, Abbott) |
2009-10 | PHASE2 |
| NCT01923558 | COMPLETED | Healthy |
Dr. Reddy's Laboratories Limited |
2010-10 | PHASE1 |
| NCT01923259 | COMPLETED | Healthy |
Dr. Reddy's Laboratories Limited |
2010-10 | PHASE1 |
| NCT01923558 | COMPLETED | Healthy |
Dr. Reddy's Laboratories Limited |
2010-10 | PHASE1 |
| NCT01923259 | COMPLETED | Healthy |
Dr. Reddy's Laboratories Limited |
2010-10 | PHASE1 |
| NCT00805792 | COMPLETED | Ischemic Stroke |
Mayo Clinic |
2008-11 | PHASE2 |
| NCT00805792 | COMPLETED | Ischemic Stroke |
Mayo Clinic |
2008-11 | PHASE2 |
| NCT00704782 | TERMINATED | Alzheimer's Disease |
Medivation, Inc. |
2008-04 | PHASE2 |
| NCT00704782 | TERMINATED | Alzheimer's Disease |
Medivation, Inc. |
2008-04 | PHASE2 |
| NCT00988598 | COMPLETED | Alzheimer's Disease |
Pfizer |
2009-10-26 | PHASE1 |
| NCT00988598 | COMPLETED | Alzheimer's Disease |
Pfizer |
2009-10-26 | PHASE1 |
| NCT01039701 | COMPLETED | Mild to Moderate Alzheimer's Disease |
AstraZeneca |
2009-12 | PHASE2 |
| NCT01097876 | COMPLETED | Healthy |
Pfizer |
2010-04 | PHASE1 |
| NCT01097876 | COMPLETED | Healthy |
Pfizer |
2010-04 | PHASE1 |
| NCT01039701 | COMPLETED | Mild to Moderate Alzheimer's Disease |
AstraZeneca |
2009-12 | PHASE2 |
| NCT01023867 | COMPLETED | Alzheimer's Disease; Dementia |
Samsung Medical Center |
2007-03 | |
| NCT01023867 | COMPLETED | Alzheimer's Disease; Dementia |
Samsung Medical Center |
2007-03 | |
| NCT00710684 | COMPLETED | Alzheimer's Disease |
GlaxoSmithKline |
2008-07-01 | PHASE2 |
| NCT00710684 | COMPLETED | Alzheimer's Disease |
GlaxoSmithKline |
2008-07-01 | PHASE2 |
| NCT01028911 | TERMINATED | Alzheimer's Disease |
Pfizer |
2009-12 | PHASE1 |
| NCT01028911 | TERMINATED | Alzheimer's Disease |
Pfizer |
2009-12 | PHASE1 |
| NCT00566501 | COMPLETED | Alzheimer's Disease |
Eisai Inc. |
2007-12-14 | PHASE3 |
| NCT00566501 | COMPLETED | Alzheimer's Disease |
Eisai Inc. |
2007-12-14 | PHASE3 |
| NCT01044342 | COMPLETED | Cognition |
AstraZeneca |
2009-12 | PHASE1 |
| NCT01042314 | COMPLETED | Alzheimer Disease |
Bristol-Myers Squibb |
2010-01 | PHASE1 |
| NCT01044342 | COMPLETED | Cognition |
AstraZeneca |
2009-12 | PHASE1 |
| NCT01042314 | COMPLETED | Alzheimer Disease |
Bristol-Myers Squibb |
2010-01 | PHASE1 |
| NCT00708552 | COMPLETED | Alzheimer's Disease |
GlaxoSmithKline |
2008-07-04 | PHASE2 |
| NCT00708552 | COMPLETED | Alzheimer's Disease |
GlaxoSmithKline |
2008-07-04 | PHASE2 |
| NCT01063556 | COMPLETED | End-Stage Renal Disease |
Eisai Co., Ltd. |
2010-02 | PHASE4 |
| NCT01063556 | COMPLETED | End-Stage Renal Disease |
Eisai Co., Ltd. |
2010-02 | PHASE4 |
| NCT00452868 | COMPLETED | Brain and Central Nervous System Tumors; Cognitive/Functional Effects; Long-term Effects Secondary to Cancer Therapy in Children; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity |
Wake Forest University Health Sciences |
2006-06 | EARLY_PHASE1 |
| NCT00543855 | COMPLETED | Dementia With Lewy Bodies (DLB) |
Eisai Co., Ltd. |
2007-11 | PHASE2 |
| NCT00452868 | COMPLETED | Brain and Central Nervous System Tumors; Cognitive/Functional Effects; Long-term Effects Secondary to Cancer Therapy in Children; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity |
Wake Forest University Health Sciences |
2006-06 | EARLY_PHASE1 |
| NCT00543855 | COMPLETED | Dementia With Lewy Bodies (DLB) |
Eisai Co., Ltd. |
2007-11 | PHASE2 |
| NCT00672945 | TERMINATED | Alzheimer's Disease |
Epix Pharmaceuticals, Inc. |
2008-04 | PHASE2 |
| NCT00693004 | TERMINATED | Alzheimer's Disease |
Epix Pharmaceuticals, Inc. |
2008-05 | PHASE2 |
| NCT00672945 | TERMINATED | Alzheimer's Disease |
Epix Pharmaceuticals, Inc. |
2008-04 | PHASE2 |
| NCT00465283 | UNKNOWN | Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder |
BeerYaakov Mental Health Center |
2007-05 | PHASE4 |
| NCT00693004 | TERMINATED | Alzheimer's Disease |
Epix Pharmaceuticals, Inc. |
2008-05 | PHASE2 |
| NCT00465283 | UNKNOWN | Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder |
BeerYaakov Mental Health Center |
2007-05 | PHASE4 |
| NCT00912457 | UNKNOWN | Obstructive Sleep Apnea |
Associacao Fundo de Incentivo a Psicofarmcologia |
2007-03 | PHASE4 |
| NCT00912457 | UNKNOWN | Obstructive Sleep Apnea |
Associacao Fundo de Incentivo a Psicofarmcologia |
2007-03 | PHASE4 |
| NCT00959881 | COMPLETED | Healthy Subjects |
Wyeth is now a wholly owned subsidiary of Pfizer |
2009-08 | PHASE1 |
| NCT01276080 | COMPLETED | Healthy |
Ranbaxy Laboratories Limited |
2009-10 | PHASE1 |
| NCT01504503 | COMPLETED | Healthy |
Dr. Reddy's Laboratories Limited |
2009-10 | PHASE1 |
| NCT00959881 | COMPLETED | Healthy Subjects |
Wyeth is now a wholly owned subsidiary of Pfizer |
2009-08 | PHASE1 |
| NCT01504516 | COMPLETED | Healthy |
Dr. Reddy's Laboratories Limited |
2009-10 | PHASE1 |
| NCT01276067 | COMPLETED | Healthy |
Ranbaxy Laboratories Limited |
2009-10 | PHASE1 |
| NCT01504516 | COMPLETED | Healthy |
Dr. Reddy's Laboratories Limited |
2009-10 | PHASE1 |
| NCT01276080 | COMPLETED | Healthy |
Ranbaxy Laboratories Limited |
2009-10 | PHASE1 |
| NCT01276067 | COMPLETED | Healthy |
Ranbaxy Laboratories Limited |
2009-10 | PHASE1 |
| NCT01504503 | COMPLETED | Healthy |
Dr. Reddy's Laboratories Limited |
2009-10 | PHASE1 |
| NCT00777608 | COMPLETED | Alzheimer's Disease |
Merck Sharp & Dohme LLC |
2008-12 | PHASE1 |
| NCT00768261 | COMPLETED | Dementia |
Washington University School of Medicine |
2004-11 | PHASE4 |
| NCT00768261 | COMPLETED | Dementia |
Washington University School of Medicine |
2004-11 | PHASE4 |
| NCT00777608 | COMPLETED | Alzheimer's Disease |
Merck Sharp & Dohme LLC |
2008-12 | PHASE1 |
| NCT00165763 | COMPLETED | Vascular Dementia |
Eisai Inc. |
2005-09 | PHASE4 |
| NCT00165763 | COMPLETED | Vascular Dementia |
Eisai Inc. |
2005-09 | PHASE4 |
| NCT00177671 | COMPLETED | Depression; Dementia |
University of Pittsburgh |
2003-12 | PHASE4 |
| NCT00177671 | COMPLETED | Depression; Dementia |
University of Pittsburgh |
2003-12 | PHASE4 |
| NCT03073876 | COMPLETED | Alzheimer Disease |
NYU Langone Health |
2005-12-01 | PHASE4 |
| NCT03073876 | COMPLETED | Alzheimer Disease |
NYU Langone Health |
2005-12-01 | PHASE4 |
| NCT00533065 | COMPLETED | Elderly |
Ludwig Boltzmann Gesellschaft |
2007-09 | |
| NCT00533065 | COMPLETED | Elderly |
Ludwig Boltzmann Gesellschaft |
2007-09 | |
| NCT00220584 | COMPLETED | Fragile X Syndrome |
Stanford University |
2005-07 | PHASE1 |
| NCT00220584 | COMPLETED | Fragile X Syndrome |
Stanford University |
2005-07 | PHASE1 |
| NCT00916383 | COMPLETED | Irritation/Irritant |
Teikoku Pharma USA, Inc. |
2009-05 | PHASE2 |
| NCT00478205 | COMPLETED | Alzheimer's Disease |
Eisai Inc. |
2007-06 | PHASE3 |
| NCT00443014 | COMPLETED | Alzheimer Disease |
University Hospital of North Norway |
2003-06 | PHASE4 |
| NCT00711204 | WITHDRAWN | Severe Alzheimer's Disease |
Eisai Inc. |
2008-01 | PHASE4 |
| NCT00478205 | COMPLETED | Alzheimer's Disease |
Eisai Inc. |
2007-06 | PHASE3 |
| NCT00916383 | COMPLETED | Irritation/Irritant |
Teikoku Pharma USA, Inc. |
2009-05 | PHASE2 |
| NCT00443014 | COMPLETED | Alzheimer Disease |
University Hospital of North Norway |
2003-06 | PHASE4 |
| NCT00711204 | WITHDRAWN | Severe Alzheimer's Disease |
Eisai Inc. |
2008-01 | PHASE4 |
| NCT00688376 | COMPLETED | Attention Impairment |
Eisai Inc. |
2008-07-02 | PHASE3 |
| NCT00688376 | COMPLETED | Attention Impairment |
Eisai Inc. |
2008-07-02 | PHASE3 |
| NCT01451749 | COMPLETED | Mild Cognitive Impairment |
North China Pharmaceutical Group Corporation |
2008-09 | PHASE3 |
| NCT01451749 | COMPLETED | Mild Cognitive Impairment |
North China Pharmaceutical Group Corporation |
2008-09 | PHASE3 |
| NCT00874939 | TERMINATED | Alzheimer's Disease; Dementia |
Merck Sharp & Dohme LLC |
2009-04-06 | PHASE1 |
| NCT00874939 | TERMINATED | Alzheimer's Disease; Dementia |
Merck Sharp & Dohme LLC |
2009-04-06 | PHASE1 |
| NCT00829816 | COMPLETED | Alzheimer's Disease |
Medivation, Inc. |
2008-12 | PHASE1 |
| NCT00423228 | COMPLETED | Moderate Alzheimer's Disease |
Debiopharm International SA |
2007-02 | |
| NCT00829816 | COMPLETED | Alzheimer's Disease |
Medivation, Inc. |
2008-12 | PHASE1 |
| NCT01023425 | COMPLETED | Alzheimer's Disease; Dementia |
Samsung Medical Center |
2008-02 | |
| NCT01023425 | COMPLETED | Alzheimer's Disease; Dementia |
Samsung Medical Center |
2008-02 | |
| NCT00423228 | COMPLETED | Moderate Alzheimer's Disease |
Debiopharm International SA |
2007-02 | |
| NCT00766363 | COMPLETED | Alzheimer's Disease; Central Nervous System Diseases |
FORUM Pharmaceuticals Inc |
2008-10 | PHASE1 |
| NCT00766363 | COMPLETED | Alzheimer's Disease; Central Nervous System Diseases |
FORUM Pharmaceuticals Inc |
2008-10 | PHASE1 |
| NCT00912808 | COMPLETED | Parkinson's Disease |
Oregon Health and Science University |
2005-10 | |
| NCT00912808 | COMPLETED | Parkinson's Disease |
Oregon Health and Science University |
2005-10 | |
| NCT00348309 | COMPLETED | Alzheimer's Disease |
GlaxoSmithKline |
2006-07-06 | |
| NCT00348309 | COMPLETED | Alzheimer's Disease |
GlaxoSmithKline |
2006-07-06 | |
| NCT00713765 | TERMINATED | Alzheimer's Disease |
AstraZeneca |
2008-12 | PHASE1 |
| NCT00571064 | COMPLETED | Mild to Severe Alzheimer's Disease |
Eisai Inc. |
2008-01 | PHASE4 |
| NCT00571064 | COMPLETED | Mild to Severe Alzheimer's Disease |
Eisai Inc. |
2008-01 | PHASE4 |
| NCT00713765 | TERMINATED | Alzheimer's Disease |
AstraZeneca |
2008-12 | PHASE1 |
| NCT00675025 | TERMINATED | Down Syndrome |
Eisai Inc. |
2008-04-04 | PHASE2 |
| NCT00675025 | TERMINATED | Down Syndrome |
Eisai Inc. |
2008-04-04 | PHASE2 |
| NCT00754052 | TERMINATED | Down Syndrome; Cognitive Dysfunction |
Eisai Inc. |
2008-09 | PHASE3 |
| NCT00754052 | TERMINATED | Down Syndrome; Cognitive Dysfunction |
Eisai Inc. |
2008-09 | PHASE3 |
| NCT00754013 | TERMINATED | Down Syndrome; Cognitive Dysfunction |
Eisai Inc. |
2008-09 | PHASE3 |
| NCT00754013 | TERMINATED | Down Syndrome; Cognitive Dysfunction |
Eisai Inc. |
2008-09 | PHASE3 |
| NCT00570128 | COMPLETED | Down Syndrome |
Eisai Inc. |
2007-11-16 | PHASE2 |
| NCT00570128 | COMPLETED | Down Syndrome |
Eisai Inc. |
2007-11-16 | PHASE2 |
| NCT00428090 | COMPLETED | Alzheimer's Disease |
GlaxoSmithKline |
2007-02-27 | PHASE3 |
| NCT00428090 | COMPLETED | Alzheimer's Disease |
GlaxoSmithKline |
2007-02-27 | PHASE3 |
| NCT00467389 | COMPLETED | Cocaine Abuse and Dependence |
US Department of Veterans Affairs |
2007-02 | PHASE2 |
| NCT00467389 | COMPLETED | Cocaine Abuse and Dependence |
US Department of Veterans Affairs |
2007-02 | PHASE2 |
| NCT00381381 | COMPLETED | Alzheimer's Disease |
Eisai Korea Inc. |
2006-05-31 | PHASE4 |
| NCT00381381 | COMPLETED | Alzheimer's Disease |
Eisai Korea Inc. |
2006-05-31 | PHASE4 |
| NCT00477659 | COMPLETED | Alzheimer's Disease |
Eisai Inc. |
2007-07-23 | PHASE4 |
| NCT00477659 | COMPLETED | Alzheimer's Disease |
Eisai Inc. |
2007-07-23 | PHASE4 |
| NCT00482001 | COMPLETED | Mental Health; Geriatrics |
Sunnybrook Health Sciences Centre |
2007-06 | PHASE4 |
| NCT00165750 | TERMINATED | Alzheimer's Disease |
Eisai Korea Inc. |
2005-03 | PHASE4 |
| NCT00501111 | COMPLETED | Alzheimer Disease |
AstraZeneca |
2007-07 | PHASE2 |
| NCT00501111 | COMPLETED | Alzheimer Disease |
AstraZeneca |
2007-07 | PHASE2 |
| NCT00482001 | COMPLETED | Mental Health; Geriatrics |
Sunnybrook Health Sciences Centre |
2007-06 | PHASE4 |
| NCT00165750 | TERMINATED | Alzheimer's Disease |
Eisai Korea Inc. |
2005-03 | PHASE4 |
| NCT00602680 | TERMINATED | Alzheimer's Disease |
Sanofi |
2008-01 | PHASE2 |
| NCT00505167 | COMPLETED | Dementia, Alzheimer Type |
Hospital Miguel Servet |
2007-07 | PHASE4 |
| NCT00505167 | COMPLETED | Dementia, Alzheimer Type |
Hospital Miguel Servet |
2007-07 | PHASE4 |
| NCT00602680 | TERMINATED | Alzheimer's Disease |
Sanofi |
2008-01 | PHASE2 |
| NCT00887601 | COMPLETED | Dementia |
Merck Sharp & Dohme LLC |
2007-08 | PHASE1 |
| NCT00887601 | COMPLETED | Dementia |
Merck Sharp & Dohme LLC |
2007-08 | PHASE1 |
| NCT00911807 | COMPLETED | Alzheimer Disease |
Ever Neuro Pharma GmbH |
2004-10 | PHASE2 |
| NCT00174382 | TERMINATED | Dementia, Vascular; Dementia, Mixed |
Pfizer |
2005-06 | PHASE3 |
| NCT01191918 | COMPLETED | Bipolar Disorder; Mania |
Shanghai Mental Health Center |
2005-05 | PHASE4 |
| NCT00174382 | TERMINATED | Dementia, Vascular; Dementia, Mixed |
Pfizer |
2005-06 | PHASE3 |
| NCT01191918 | COMPLETED | Bipolar Disorder; Mania |
Shanghai Mental Health Center |
2005-05 | PHASE4 |
| NCT00911807 | COMPLETED | Alzheimer Disease |
Ever Neuro Pharma GmbH |
2004-10 | PHASE2 |
| NCT00151398 | COMPLETED | Alzheimer Disease |
Wyeth is now a wholly owned subsidiary of Pfizer |
2005-10-06 | PHASE2 |
| NCT00151398 | COMPLETED | Alzheimer Disease |
Wyeth is now a wholly owned subsidiary of Pfizer |
2005-10-06 | PHASE2 |
| NCT00519298 | COMPLETED | Healthy; Adult |
Wyeth is now a wholly owned subsidiary of Pfizer |
2007-10 | PHASE1 |
| NCT01297036 | COMPLETED | Alzheimer Disease |
Korea University Anam Hospital |
2008-01 | PHASE1 |
| NCT00403520 | COMPLETED | Alzheimer's Disease |
Eisai Inc. |
2006-11 | PHASE4 |
| NCT00519298 | COMPLETED | Healthy; Adult |
Wyeth is now a wholly owned subsidiary of Pfizer |
2007-10 | PHASE1 |
| NCT00403520 | COMPLETED | Alzheimer's Disease |
Eisai Inc. |
2006-11 | PHASE4 |
| NCT01297036 | COMPLETED | Alzheimer Disease |
Korea University Anam Hospital |
2008-01 | PHASE1 |
| NCT00428389 | COMPLETED | Alzheimer's Disease |
Novartis |
2007-01 | PHASE3 |
| NCT00428389 | COMPLETED | Alzheimer's Disease |
Novartis |
2007-01 | PHASE3 |
| NCT00384423 | COMPLETED | Alzheimer's Disease |
Epix Pharmaceuticals, Inc. |
2006-10 | PHASE2 |
| NCT01181310 | COMPLETED | Dementia |
Merck Sharp & Dohme LLC |
2007-06 | PHASE1 |
| NCT00384423 | COMPLETED | Alzheimer's Disease |
Epix Pharmaceuticals, Inc. |
2006-10 | PHASE2 |
| NCT01181310 | COMPLETED | Dementia |
Merck Sharp & Dohme LLC |
2007-06 | PHASE1 |
| NCT00934375 | COMPLETED | Mild Cognitive Impairment |
Eisai Inc. |
2006-02 | PHASE4 |
| NCT02988908 | COMPLETED | Memory |
Stanford University |
2000-04 | PHASE4 |
| NCT00934375 | COMPLETED | Mild Cognitive Impairment |
Eisai Inc. |
2006-02 | PHASE4 |
| NCT02988908 | COMPLETED | Memory |
Stanford University |
2000-04 | PHASE4 |
| NCT01439230 | COMPLETED | Healthy |
Teva Pharmaceuticals USA |
2007-06 | PHASE1 |
| NCT01439230 | COMPLETED | Healthy |
Teva Pharmaceuticals USA |
2007-06 | PHASE1 |
| NCT00352664 | TERMINATED | Advanced Cancer |
M.D. Anderson Cancer Center |
2003-11 | PHASE3 |
| NCT00267163 | COMPLETED | Cognition Disorders |
National Institute on Aging (NIA) |
2000-09 | PHASE4 |
| NCT00352664 | TERMINATED | Advanced Cancer |
M.D. Anderson Cancer Center |
2003-11 | PHASE3 |
| NCT01439243 | COMPLETED | Healthy |
Teva Pharmaceuticals USA |
2007-06 | PHASE1 |
| NCT00267163 | COMPLETED | Cognition Disorders |
National Institute on Aging (NIA) |
2000-09 | PHASE4 |
| NCT01439243 | COMPLETED | Healthy |
Teva Pharmaceuticals USA |
2007-06 | PHASE1 |
| NCT00800553 | COMPLETED | Sleep Deprivation |
Duke-NUS Graduate Medical School |
2006-11 | PHASE4 |
| NCT00800553 | COMPLETED | Sleep Deprivation |
Duke-NUS Graduate Medical School |
2006-11 | PHASE4 |
| NCT00230568 | COMPLETED | Alzheimer's Disease |
Eisai Inc. |
2005-12 | PHASE4 |
| NCT00182884 | COMPLETED | Postoperative Complications; Delirium |
Indiana University Health |
2004-07 | PHASE4 |
| NCT00182845 | COMPLETED | Postoperative Complications; Delirium |
Pfizer |
2005-02 | PHASE4 |
| NCT00182884 | COMPLETED | Postoperative Complications; Delirium |
Indiana University Health |
2004-07 | PHASE4 |
| NCT00182845 | COMPLETED | Postoperative Complications; Delirium |
Pfizer |
2005-02 | PHASE4 |
| NCT00230568 | COMPLETED | Alzheimer's Disease |
Eisai Inc. |
2005-12 | PHASE4 |
| NCT00293176 | COMPLETED | Memory Loss |
Eisai Inc. |
2003-12 | PHASE4 |
| NCT00293176 | COMPLETED | Memory Loss |
Eisai Inc. |
2003-12 | PHASE4 |
| NCT00043589 | COMPLETED | Memory Disorders |
Stanford University |
2002-06 | |
| NCT00043589 | COMPLETED | Memory Disorders |
Stanford University |
2002-06 | |
| NCT00103948 | COMPLETED | Cognitive Impairment |
Eisai Limited |
2005-02 | PHASE2 |
| NCT00103948 | COMPLETED | Cognitive Impairment |
Eisai Limited |
2005-02 | PHASE2 |
| NCT00047697 | COMPLETED | Autistic Disorder |
University of Pittsburgh |
2002-10 | PHASE2 |
| NCT00047697 | COMPLETED | Autistic Disorder |
University of Pittsburgh |
2002-10 | PHASE2 |
| NCT00165724 | COMPLETED | Alzheimer's Disease |
Eisai Korea Inc. |
2004-06-30 | PHASE4 |
| NCT00165724 | COMPLETED | Alzheimer's Disease |
Eisai Korea Inc. |
2004-06-30 | PHASE4 |
| NCT01327859 | COMPLETED | Parkinson's Disease; Dementia |
Eisai Inc. |
2003-03 | PHASE3 |
| NCT01327859 | COMPLETED | Parkinson's Disease; Dementia |
Eisai Inc. |
2003-03 | PHASE3 |
| NCT01260948 | COMPLETED | Healthy |
Teva Pharmaceuticals USA |
2006-04 | PHASE1 |
| NCT01260922 | COMPLETED | Healthy |
Teva Pharmaceuticals USA |
2006-04 | PHASE1 |
| NCT01260922 | COMPLETED | Healthy |
Teva Pharmaceuticals USA |
2006-04 | PHASE1 |
| NCT01260948 | COMPLETED | Healthy |
Teva Pharmaceuticals USA |
2006-04 | PHASE1 |
| NCT00165737 | COMPLETED | Dementia, Vascular |
Eisai Inc. |
2003-03 | PHASE3 |
| NCT00165737 | COMPLETED | Dementia, Vascular |
Eisai Inc. |
2003-03 | PHASE3 |
| NCT00096473 | COMPLETED | Alzheimer's Disease; Dementia |
Eisai Inc. |
2001-01 | PHASE3 |
| NCT00234637 | COMPLETED | Alzheimer's Disease |
Novartis |
2003-11 | PHASE4 |
| NCT00096473 | COMPLETED | Alzheimer's Disease; Dementia |
Eisai Inc. |
2001-01 | PHASE3 |
| NCT00234637 | COMPLETED | Alzheimer's Disease |
Novartis |
2003-11 | PHASE4 |
| NCT00070161 | COMPLETED | Brain and Central Nervous System Tumors; Radiation Toxicity |
Wake Forest University Health Sciences |
2001-07-01 | PHASE2 |
| NCT00070161 | COMPLETED | Brain and Central Nervous System Tumors; Radiation Toxicity |
Wake Forest University Health Sciences |
2001-07-01 | PHASE2 |
| NCT00165659 | COMPLETED | Alzheimer Disease |
Eisai Limited |
2002-11 | PHASE2 |
| NCT00165659 | COMPLETED | Alzheimer Disease |
Eisai Limited |
2002-11 | PHASE2 |
| NCT00006349 | COMPLETED | Cognitive/Functional Effects; Delirium; Depression; Lung Cancer; Radiation Toxicity |
Alliance for Clinical Trials in Oncology |
2001-02 | PHASE3 |
| NCT00227994 | COMPLETED | Cerebrovascular Accident |
University of Pittsburgh |
2003-04 | PHASE4 |
| NCT00006349 | COMPLETED | Cognitive/Functional Effects; Delirium; Depression; Lung Cancer; Radiation Toxicity |
Alliance for Clinical Trials in Oncology |
2001-02 | PHASE3 |
| NCT00206947 | TERMINATED | Schizophrenia |
Birte Glenthoj |
2002-12 | PHASE2 |
| NCT00227994 | COMPLETED | Cerebrovascular Accident |
University of Pittsburgh |
2003-04 | PHASE4 |
| NCT00206947 | TERMINATED | Schizophrenia |
Birte Glenthoj |
2002-12 | PHASE2 |
| NCT00042172 | COMPLETED | Cognition Disorders; Alzheimer Disease |
University of Iowa |
2002-06 | PHASE4 |
| NCT00042172 | COMPLETED | Cognition Disorders; Alzheimer Disease |
University of Iowa |
2002-06 | PHASE4 |
| NCT01146509 | COMPLETED | Migraine Headache |
Eisai Inc. |
2003-01 | PHASE2 |
| NCT01146509 | COMPLETED | Migraine Headache |
Eisai Inc. |
2003-01 | PHASE2 |
| NCT00006399 | COMPLETED | Alzheimer Disease |
National Center for Research Resources (NCRR) |
1999-09 | PHASE2 |
| NCT00006399 | COMPLETED | Alzheimer Disease |
National Center for Research Resources (NCRR) |
1999-09 | PHASE2 |
| NCT00000173 | COMPLETED | Alzheimer Disease |
National Institute on Aging (NIA) |
1999-03 | PHASE3 |
| NCT00000173 | COMPLETED | Alzheimer Disease |
National Institute on Aging (NIA) |
1999-03 | PHASE3 |
| NCT00015132 | COMPLETED | Cocaine-Related Disorders |
National Institute on Drug Abuse (NIDA) |
1999-03 | PHASE2 |
| NCT00015132 | COMPLETED | Cocaine-Related Disorders |
National Institute on Drug Abuse (NIDA) |
1999-03 | PHASE2 |
| NCT00530478 | UNKNOWN | Stroke |
Samsung Medical Center |
||
| NCT00004807 | COMPLETED | Rett Syndrome |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
1995-01 | |
| NCT00190021 | UNKNOWN | Dementia of Alzheimer Type |
Beersheva Mental Health Center |
PHASE3 | |
| NCT00030979 | COMPLETED | Parkinson Disease |
National Institute of Neurological Disorders and Stroke (NINDS) |
2002-02 | PHASE4 |
| NCT00165815 | COMPLETED | Dementia With Parkinson's Disease |
Eisai Limited |
2002-08 | PHASE3 |
| NCT00035204 | COMPLETED | Alzheimer Disease |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
PHASE4 | |
| NCT00483028 | COMPLETED | Alzheimer's Disease |
Pfizer |
2004-06 | |
| NCT00142324 | UNKNOWN | Alzheimer's Disease |
Institute of Psychiatry, London |
2003-11 | PHASE4 |
| NCT00348192 | COMPLETED | Alzheimer's Disease |
GlaxoSmithKline |
2006-05 | PHASE2 |
| NCT00196690 | COMPLETED | Stroke; Aphasia |
Gabinete Berthier y Martínez |
2003-02 | PHASE4 |
| NCT00139373 | UNKNOWN | Supranuclear Palsy, Progressive |
Groupe Hospitalier Pitie-Salpetriere |
PHASE2 | |
| NCT00630851 | COMPLETED | Alzheimer Disease |
Pfizer |
2002-10 | PHASE3 |
| NCT00467766 | COMPLETED | Alzheimer Disease; Caregivers |
Pfizer |
1999-07 | |
| NCT00069550 | UNKNOWN | Rett Syndrome |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
2004-09 | PHASE3 |
| NCT00004807 | COMPLETED | Rett Syndrome |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
1995-01 | |
| NCT00030979 | COMPLETED | Parkinson Disease |
National Institute of Neurological Disorders and Stroke (NINDS) |
2002-02 | PHASE4 |
| NCT00165815 | COMPLETED | Dementia With Parkinson's Disease |
Eisai Limited |
2002-08 | PHASE3 |
| NCT00035204 | COMPLETED | Alzheimer Disease |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
PHASE4 | |
| NCT01419340 | COMPLETED | Healthy |
Torrent Pharmaceuticals Limited |
PHASE1 | |
| NCT00142324 | UNKNOWN | Alzheimer's Disease |
Institute of Psychiatry, London |
2003-11 | PHASE4 |
| NCT00196690 | COMPLETED | Stroke; Aphasia |
Gabinete Berthier y Martínez |
2003-02 | PHASE4 |
| NCT00315367 | COMPLETED | Relapsing-Remitting Multiple Sclerosis |
Neurognostics |
2004-09 | PHASE4 |
| NCT00467766 | COMPLETED | Alzheimer Disease; Caregivers |
Pfizer |
1999-07 | |
| NCT00062972 | WITHDRAWN | Multiple Sclerosis |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
1999-09 | PHASE3 |
| NCT00480870 | COMPLETED | Alzheimer Disease; Sleep Apnea, Obstructive |
Associacao Fundo de Incentivo a Psicofarmcologia |
1999-04 | PHASE4 |
| NCT01419340 | COMPLETED | Healthy |
Torrent Pharmaceuticals Limited |
PHASE1 | |
| NCT00188812 | COMPLETED | Dementia Associated With Cerebrovascular Disease |
University Health Network, Toronto |
2004-05 | PHASE3 |
| NCT01419366 | COMPLETED | Healthy |
Torrent Pharmaceuticals Limited |
PHASE1 | |
| NCT00315367 | COMPLETED | Relapsing-Remitting Multiple Sclerosis |
Neurognostics |
2004-09 | PHASE4 |
| NCT00220896 | COMPLETED | Cognitively Normal Elderly Individuals |
Technical University of Munich |
2006-01 | PHASE4 |
| NCT00062972 | WITHDRAWN | Multiple Sclerosis |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
1999-09 | PHASE3 |
| NCT00530478 | UNKNOWN | Stroke |
Samsung Medical Center |
||
| NCT00190021 | UNKNOWN | Dementia of Alzheimer Type |
Beersheva Mental Health Center |
PHASE3 | |
| NCT00480870 | COMPLETED | Alzheimer Disease; Sleep Apnea, Obstructive |
Associacao Fundo de Incentivo a Psicofarmcologia |
1999-04 | PHASE4 |
| NCT00483028 | COMPLETED | Alzheimer's Disease |
Pfizer |
2004-06 | |
| NCT00348192 | COMPLETED | Alzheimer's Disease |
GlaxoSmithKline |
2006-05 | PHASE2 |
| NCT00188812 | COMPLETED | Dementia Associated With Cerebrovascular Disease |
University Health Network, Toronto |
2004-05 | PHASE3 |
| NCT00139373 | UNKNOWN | Supranuclear Palsy, Progressive |
Groupe Hospitalier Pitie-Salpetriere |
PHASE2 | |
| NCT01419366 | COMPLETED | Healthy |
Torrent Pharmaceuticals Limited |
PHASE1 | |
| NCT00630851 | COMPLETED | Alzheimer Disease |
Pfizer |
2002-10 | PHASE3 |
| NCT00220896 | COMPLETED | Cognitively Normal Elderly Individuals |
Technical University of Munich |
2006-01 | PHASE4 |
| NCT00069550 | UNKNOWN | Rett Syndrome |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
2004-09 | PHASE3 |
(data from https://clinicaltrials.gov, updated on 2026-08-17)
Check the
Donepezil
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Note: Technical data last updated: Sep 1, 2026.